Category
Biosimilars
2 articles
PBSprice disclosure
Pharmaceutical Price Disclosure in Australia: How the PBS Cost Reduction Mechanism Works
Australia's price disclosure regime requires pharmaceutical manufacturers to disclose actual transaction prices, triggering mandatory PBS price reductions. A policy analysis of how the mechanism works, its impact on medicine affordability, and reform priorities.
10 May 202612 min read
TGAmedicines regulation
TGA Reform Priorities for 2027: Accelerating Access to Medicines for Australians
Australia's Therapeutic Goods Administration faces mounting pressure to modernise its approval pathways, expand biosimilar uptake, close the digital therapeutics regulatory gap, and strengthen post-market surveillance. A policy analysis of the reform agenda for 2027.
9 May 202612 min read